Daniel P T, Dörken B
Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum, Humboldt Universität, Berlin, Germany.
Internist (Berl). 2005 Aug;46(8):835-6, 838-42, 844-6. doi: 10.1007/s00108-005-1470-1.
Recent insights in disease pathogenesis and mechanisms of resistance to therapy of malignant tumors provide a rational basis for the development of novel therapeutic strategies that target genetic defects and deregulated signaling events in malignant tumors. In contrast to conventional therapeutics, small molecule inhibitors or monoclonal antibodies allow for a far more selective, targeted therapy of tumors that carry a corresponding target structure or gene expression profile. Molecular therapeutics therefore necessitate clinical deployment of genetic diagnostics for the identification of those patients who have a chance to benefit from these novel targeted therapies.
近期对恶性肿瘤疾病发病机制及治疗耐药机制的深入了解，为开发针对恶性肿瘤中基因缺陷和失调信号事件的新型治疗策略提供了合理依据。与传统疗法不同，小分子抑制剂或单克隆抗体能够对具有相应靶标结构或基因表达谱的肿瘤进行更具选择性的靶向治疗。因此，分子治疗需要临床应用基因诊断来识别那些有机会从这些新型靶向治疗中获益的患者。
